Pharmaceutical pricing pressure remains post the US election with a focus on headline costs per patient (eg Gilead Sciences, Mylan and, more recently, Marathon Pharma). A lack of clarity surrounding ways in which high pricing will be dealt with by the Trump administration has taken some momentum out of healthcare stocks. Investors are subsequently looking for ways to mitigate this risk exposure and may turn to the diagnostics sector go